Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.39 |
| ▸ | PARP1 | P09874 | 4/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23142225 | 0.85 | PNMT (0.50) | PNMTPARP1PARP2 | |
| SCHEMBL23142306 | 0.79 | PNMT (0.45) | PNMTDAOALDH1A1 | |
| SCHEMBL12563262 | 0.79 | PNMT (0.62) | PNMTPARP1PARP2TLR9TLR8 | |
| SCHEMBL23142158 | 0.79 | PNMT (0.42) | PNMTPARP1PARP2 | |
| SCHEMBL21236155 | 0.76 | PNMT (0.63) | PNMTPARP1PARP2 | |
| SCHEMBL2994813 | 0.75 | PNMT (0.38) | PNMTPARP1PARP2ALDH1A1TLR9 | |
| SCHEMBL12538521 | 0.75 | PNMT (0.38) | PNMTPARP1PARP2ALDH1A1TLR9 | |
| SCHEMBL6424933 | 0.74 | ALDH1A1 (0.65) | PNMTDAOALDH1A1 | |
| SCHEMBL2761783 | 0.70 | KDM4E (0.54) | PNMTDAOALDH1A1 | |
| SCHEMBL28981445 | 0.69 | PNMT (0.39) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. | 2024-12-03 | — | — | US | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| CN-110511220-B | P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine | 上海挚盟医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| EP-3798220-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2021-03-31 | — | — | EP | disclosed |
| EP-3798220-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2021-03-31 | — | — | EP | disclosed |
| CN-112119079-A | P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine | 上海挚盟医药科技有限公司 | 2020-12-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | PNMT 149/4885PARP1 3815/4885PARP2 3899/4885 |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | PNMT 149/4885PARP1 3815/4885PARP2 3899/4885 |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | PNMT 146/4885PARP1 3724/4885PARP2 3860/4885 |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | PNMT 146/4885PARP1 3724/4885PARP2 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.